Effect of p-glycoprotein on flavopiridol sensitivity

British Journal of Cancer

Volumn 84, Issue 10, 2001, Pages 1391-1396

  Boerner, S A ^a   Tourne, M E ^b   Kaufmann, S H ^a,b   Bible, K C ^b  

^a Divisions of Oncology Research and

^b MAYO CLINIC   (United States)

Author keywords

Chemotherapy; Cyclin dependent kinase; Drug resistance; Flavonoids

Indexed keywords

AZIDOPINE; COLCHICINE; FLAVOPIRIDOL; GLYCOPROTEIN P; QUINIDINE; VERAPAMIL;

ANIMAL CELL; ARTICLE; CHO CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG PROTEIN BINDING; DRUG SENSITIVITY; FEMALE; FLOW CYTOMETRY; MEMBRANE VESICLE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL SURVIVAL; CHO CELLS; CISPLATIN; COLCHICINE; COLONY-FORMING UNITS ASSAY; CRICETINAE; DRUG RESISTANCE, MULTIPLE; FLAVONOIDS; P-GLYCOPROTEIN; PACLITAXEL; PIPERIDINES; QUINIDINE; VERAPAMIL;

EID: 0035906857     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.2000.1688     Document Type: Article

References (45)

1. Flavopiridol induces apoptosis of normal lymphoid cells. Causes immunosuppression, and has potent antitumor activity in vivo against human leukemia and lymphoma xenografts
2. Pleiotropic phenotype of colchicine-resistant CHO cells: Cross-resistance and collateral sensitivity
3. Characterization of a human myeloid leukemia cell line highly resistant to taxol
4. Flavopiridol (NSC 649890, L86-8275): A cytotoxic flavone that induces cell death in human lung carcinoma cells
5. Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: Importance of sequence of administration
6. Characterization of an ovarian carcinoma cell line resistant to cisplatin and flavopiridol
7. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding
8. Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance
9. Cell cycle-independent induction of apoptosis by the anti-tumor drug flavopiridol in endothelial cells
10. Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence upon functional p53
11. 1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells
12. Inhibition of drug transport by genistein in multidrug-resistant cells expressing P-glycoprotein
13. Effect of calcium antagonists on the chemosensitivity of two multidrug-resistant human tumour cell lines which do not overexpress P-glycoprotein
14. Flavonoids: A class of modulators with bifunctional interactions at vicinal ATP- and steroid-binding sites on mouse P-glycoprotein
15. Modulation of adriamycin accumulation and efflux by flavonoids in HCT- 15 colon cells. Activation of P-glycoprotein as a putative mechanism
16. Antitumoral activity of flavone L86-8275
17. Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase
18. Flavopiridol (L86-8275): Selective antitumor in vitro and activity in vivo for prostate carcinoma cells
19. P-glycoprotein-mediated multidrug resistance: Experimental and clinical strategies for its reversal
20. Expression of a multidrug resistance gene in human cancers
21. Electrophoretic analysis of P-glycoproteins produced by mouse J774.2 and Chinese hamster ovary multidrug-resistant cells
22. 1-adrenergic receptor and the calcium channel bind to a common domain in P-glycoprotein
23. Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue
24. Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies
25. Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275
26. Multidrug resistance: Clinical relevance in solid turnouts and strategies for circumvention
27. The novel cyclin-dependent kinase inhibitor flavopiridol downregulates Bcl-2 and induces growth arrest and apoptosis in chronic B-cell leukemia lines
28. + gradient-stimulated uptake
29. Multidrug resistance: Molecular mechanisms and clinical relevance
30. Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275
31. Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol
32. Flavopiridol, a novel cyclin dependent kinase inhibitor, suppresses the growth of squamous cell carcinomas of the head and neck by inducing apoptosis
33. Amplification of P-glycoprotein genes in multidrug-resistant mammalian cell lines
34. Identification of the multidrug resistance-related membrane glycoprotein as an acceptor for calcium channel blockers
35. Breast cancer resistance protein (BCRP)-associated drug export and p53 inactivation impact flavopiridol (FLA) antitumor activity
36. Potentiation of apoptosis by flavopiridol in mitomycin-C-treated gastric and breast cancer cells
37. Flavopiridol (L86 8275; NSC 649890), a new kinase inhibitor for tumor therapy
38. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms
39. Evaluation of 2,6-diamino-N-([1-oxotridecyl)-2-piperidinyl)methyl)-hexanamide (NPC 15437), a protein kinase C inhibitor, as a modulator of P-glycoprotein-mediated in vitro
40. Overexpression and amplification of five genes in a multidrug-resistant chinese hamster ovary cell line
41. Multidrug resistance and its reversal
42. Cell-cycle arrest versus cell death in cancer therapy
43. Single cell analysis of daunomycin uptake and efflux in multi-drug-resistant and -sensitive KB cells: Effects of verapamil and other drugs
44. Clinical trials of flavopiridol
45. Progesterone interacts with P-glycoprotein in multidrug-resistant cells and in the endometrium of gravid uterus